- Home
- MYGN vs RELY Comparison
MYGN vs RELY Comparison
Compare MYGN & RELY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYGN | RELY |
|---|---|---|
| Founded | 1991 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.5M | 2.6B |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MYGN | RELY |
|---|---|---|
| Price | $6.54 | $14.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 10 |
| Target Price | $11.82 | ★ $26.00 |
| AVG Volume (30 Days) | 1.1M | ★ 3.3M |
| Earning Date | 11-03-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.09 |
| Revenue | $825,300,000.00 | ★ $1,544,865,000.00 |
| Revenue This Year | $0.10 | $30.78 |
| Revenue Next Year | $5.28 | $18.39 |
| P/E Ratio | ★ N/A | $155.13 |
| Revenue Growth | 0.21 | ★ 31.27 |
| 52 Week Low | $3.76 | $12.08 |
| 52 Week High | $15.47 | $27.32 |
Technical Indicators
Market Signals| Indicator | MYGN | RELY |
|---|---|---|
| Relative Strength Index (RSI) | 38.37 | 57.52 |
| Support Level | $7.15 | $13.95 |
| Resistance Level | $7.20 | $14.78 |
| Average True Range (ATR) | 0.29 | 0.52 |
| MACD | -0.07 | 0.17 |
| Stochastic Oscillator | 0.00 | 62.98 |
Price Performance
Historical ComparisonAbout MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About RELY Remitly Global Inc.
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.